DexCom Investors Get Late-December Lead Deadlines in Suits Alleging Unauthorized CGM Changes

Overview

• DexCom is the target of securities class actions alleging the company made FDA-unauthorized design changes to its G6 and G7 glucose monitors that reduced reliability and posed health risks.
• The Rosen Law Firm set a December 29, 2025 deadline for investors to seek lead-plaintiff status using a class period of July 26, 2024 through September 17, 2025.
• The Gross Law Firm and Kessler Topaz notices use a broader class period of January 8, 2024 through September 17, 2025 and cite a December 26, 2025 lead-plaintiff deadline.
• Complaints contend DexCom overstated the G7’s enhancements, reliability, accuracy, and functionality and downplayed the scope of problems tied to adulterated devices.
• Notices emphasize that a lawsuit has been filed but no class has been certified, and investors may choose to seek lead status or remain absent without affecting eligibility to share in any potential recovery.